Evidence map›Paper›PMID 39192597›Full record

Trial reportCancer2025

Moderately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS): Updated local control, late toxicities, and patient-reported outcomes.

Andrew J Bishop, Devarati Mitra, Ahsan Farooqi, David M Swanson, Caroline Hempel, Tiara Willis, Chris Pearlnath, Wei-Lien Wang, Ravin Ratan, Neeta Somaiah and 12 more

2 registry-linked trialsAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03819985 phase2active not recruitingnot on this map

Prospective Trial of Hypofractionated Pre-Operative Radiation Therapy for Localized, Resectable Soft Tissue Sarcoma of the Extremity or Superficial Trunk (HYPORT-STS)

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2018 to 2027Enrolled122ConditionsResectable Soft Tissue Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8ArmsHypofractionated Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration
NCT07265661 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

Surgical Timing After Preoperative Hypofractionated Radiotherapy for Patients With Primary Localized Soft Tissue Sarcoma of the Extremity and Trunk: a Randomized Phase 2 Clinical Trial

TypeinterventionalSponsorItalian Sarcoma GroupRan2026 to 2035Enrolled142ConditionsSoft Tissue Sarcoma of the Trunk and ExtremitiesArmshypofractionated radiotherapy (30Gy/5 fractions) and surgical resection at 1-2 weeks after treatment, hypofractionated radiotherapy (30Gy/5 fractions) and surgical resection at 4-6 weeks after treatment
3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Andrew J BishopDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-7737-8023
Devarati MitraDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-2225-164X
Ahsan FarooqiDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
David M SwansonDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Caroline HempelDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tiara WillisDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Chris PearlnathDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wei-Lien WangDepartment of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ravin RatanDepartment of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Neeta SomaiahDepartment of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-0146-7732
Robert S BenjaminDepartment of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-2589-5870
Keila E TorresDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Kelly K HuntDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christopher P ScallyDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Emily Z KeungDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-8783-8484
Robert L SatcherDepartment of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Justin E BirdDepartment of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Patrick P LinDepartment of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Bryan S MoonDepartment of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Valerae O LewisDepartment of Orthopedic Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christina L RolandDepartment of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-3400-0087
B Ashleigh GuadagnoloDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672NIH HHS CA016672
6 · The paper itself

Abstract

backgroundModerately hypofractionated, preoperative radiotherapy in patients with soft tissue sarcomas (HYPORT-STS; ClinicalTrials.gov identifier NCT03819985) investigated a radiobiologically equivalent, moderately hypofractionated course of preoperative radiotherapy (RT) 15 × 2.85 Gy in patients with soft tissue sarcoma (STS). Here, the authors report longer term follow-up to update local control and report late toxicities, as well as functional and patient-reported outcomes.

methodsHYPORT-STS was a single-center, open-label, single-arm, prospective phase 2 clinical trial that enrolled 120 eligible adult patients with localized STS of the extremities or superficial trunk between 2018 and 2021. Patients received a 3-week course of preoperative RT followed by surgery 4-8 weeks later. End points and follow-up were analyzed from the date of surgery.

resultsThe median follow-up was 43 months (interquartile range, 37-52 months), and the 4-year local recurrence-free survival rate was 93%. Overall RT-related late toxicities improved with time from local therapy (p < .001), and few patients had grade ≥2 toxicities (9%; n = 8 of 88) at 2 years. These included: 2% grade ≥2 skin toxicity, 2% fibrosis, 3% lymphedema, and 1% joint stiffness. Four patients (3%) had bone fractures. Both functional outcomes, as measured by the Musculoskeletal Tumor Society Rating Scale (p < .001), and quality of life, as measured by the Functional Assessment of Cancer Therapy-General (p < .001), improved with time from treatment, and both measures were better in follow-up at 2 years compared with baseline.

conclusionsLong-term follow up suggests that moderately hypofractionated preoperative RT for patients with STS is safe and effective. Higher grade late toxicities affect a minority of patients. Late toxicities decrease over time, whereas functional outcomes and health-related quality of life seem to improve with more time from combined modality treatment.

Indexed as

Patient Reported Outcome MeasuresPreoperative CareRadiation Dose HypofractionationSarcomaSoft Tissue NeoplasmsAdultAgedFemaleFollow-Up StudiesHumansMaleMiddle AgedProspective StudiesQuality of Lifehypofractionatedhypofractionationpreoperativeradiationradiation therapysarcomasoft tissue

Identifiers

PMID39192597
PMCPMC11695168

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.